Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03370289
Recruitment Status : Completed
First Posted : December 12, 2017
Results First Posted : July 29, 2019
Last Update Posted : July 29, 2019
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.

Condition or disease Intervention/treatment Phase
Pandemic Influenza Prevention Biological: BLB-750 Vaccine (Qinghai RG strain) Phase 4

Detailed Description:

The drug being tested in this study is called BLB-750 that is a vaccine for pandemic influenza infection. This study will evaluate immunogenicity and safety of two intramuscular vaccinations with BLB-750 at 3-week intervals in healthy Japanese adults. The study will enroll 55 participants. BLB-750 will be administered in opened manner:

- Two intramuscular vaccinations of BLB-750 at 3-week intervals, 0.5 mL

This trial will be conducted in Japan. The overall time to participate in this study will be 43 days, starting on the day of first vaccination. Participants will make multiple visits to the clinic, including 21 days after the first vaccination and 21 days after the second vaccination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-label Phase 4 Study to Evaluate the Immunogenicity and Safety of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
Actual Study Start Date : January 12, 2018
Actual Primary Completion Date : February 28, 2018
Actual Study Completion Date : February 28, 2018

Arm Intervention/treatment
Experimental: BLB-750 Qinghai RG strain
Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
Biological: BLB-750 Vaccine (Qinghai RG strain)
BLB-750 Injection
Other Name: Cell-Culture Influenza Vaccine H5N1 "Takeda"




Primary Outcome Measures :
  1. Seroprotection Rate as Measured by Single Radial Hemolysis (SRH) Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination [ Time Frame: Day 43 (21 days after the second vaccination) ]
    Seroprotection rate was measured by SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after second vaccination. Seroprotection rate as SRH antibody titer is defined as the percentage of participants with SRH antibody titer ≥25 mm^2.

  2. Seroconversion Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination [ Time Frame: Day 43 (21 days after the second vaccination) ]
    Seroconversion rate was measured by SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after second vaccination. Seroconversion rate as SRH antibody titer is defined as the percentage of participants with a 50% or more increase in SRH antibody titer from baseline for those who have a baseline value >4 mm^2 or SRH antibody titer ≥25 mm^2 for those who have a baseline value ≤4 mm^2.

  3. Geometric Mean Fold Increase (GMFI) in SRH Antibody Titer From Baseline for the Vaccine Strain at 21 Days After the Second Vaccination [ Time Frame: Day 43 (21 days after the second vaccination) ]
    GMFI was measured as geometric mean fold change from baseline in SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after second vaccination.


Secondary Outcome Measures :
  1. Seroprotection Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the First Vaccination [ Time Frame: Day 22 (21 days after the first vaccination) ]
    Seroprotection rate was measured by SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after first vaccination. Seroprotection rate as SRH antibody titer is defined as the percentage of participants with SRH antibody titer ≥25 mm^2.

  2. Seroconversion Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the First Vaccination [ Time Frame: Day 22 (21 days after the first vaccination) ]
    Seroconversion rate was measured by SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after first vaccination. Seroconversion rate as SRH antibody titer is defined as the percentage of participants with a 50% or more increase in SRH antibody titer from baseline for those who have a baseline value >4 mm^2 or SRH antibody titer ≥25 mm^2 for those who have a baseline value ≤4 mm^2.

  3. GMFI in SRH Antibody Titer From Baseline for the Vaccine Strain at 21 Days After the First Vaccination [ Time Frame: Day 22 (21 days after the first vaccination) ]
    GMFI was measured as geometric mean fold change from baseline in SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after first vaccination.

  4. Geometric Mean Titer (GMT) of SRH Antibody Titer for the Vaccine Strain at 21 Days After Each Vaccination [ Time Frame: Day 22, and Day 43 (21 days after the first and the second vaccination) ]
    GMT was measured by SRH antibody titer for BLB-750 Qinghai RG strain at 21 days after first and second vaccination.

  5. Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE) [ Time Frame: Up to Day 43 ]
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

  6. Number of Participants With Adverse Events Related to Solicited Local and Systemic Adverse Events to be Recorded in the Participant Diary [ Time Frame: Up to Day 43 ]
    Local reactions and systemic events were recorded using a diary.

  7. Change From Baseline in Mean Systolic Blood Pressure at Specific Time Points After Vaccination [ Time Frame: Baseline, At 30 minutes after the first vaccination and on Day 22 after the first vaccination, and at 30 minutes after the second vaccination and on Day 22 after the second vaccination ]
  8. Change From Baseline in Mean Diastolic Blood Pressure at Specific Time Points After Vaccination [ Time Frame: Baseline, At 30 minutes after the first vaccination and on Day 22 after the first vaccination, and at 30 minutes after the second vaccination and on Day 22 after the second vaccination ]
  9. Change From Baseline in Mean Pulse Rate at Specific Time Points After Vaccination [ Time Frame: At 30 minutes after the first vaccination and on Day 22 after the first vaccination, and at 30 minutes after the second vaccination and on Day 22 after the second vaccination ]
  10. Change From Baseline in Mean Respiratory Rate at 30 Minutes After Vaccination [ Time Frame: Baseline, At 30 minutes after the first vaccination, and at 30 minutes after the second vaccination ]
  11. Mean Body Temperature at Specific Time Points After Vaccination [ Time Frame: Baseline, Days 1, 2, 3, 4, 5, 6, 7, and 22 after the first vaccination, Days 1, 2, 3, 4, 5, 6, 7, and 22 after the second vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
  3. The participant is a healthy Japanese adult man or woman.
  4. The participant is aged 20 to 49 years, inclusive, at the time of informed consent.
  5. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.

Exclusion Criteria:

  1. The participant has received vaccination with any other investigational products within 4 months prior to vaccination with the study drug.
  2. The participant has a history of vaccination with an H5N1 influenza vaccine.
  3. The participant has a history of infection with H5N1 virus.
  4. The participant is at high risk of contracting H5N1 influenza infection (e.g., poultry workers).
  5. The participant is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant has poorly controlled, clinically significant manifestations of neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, endocrine, or other disorders, which may impact their ability to participate as participants or may potentially confound the study results.
  7. The participant has a body temperature (oral) ≥37.5°C prior to vaccination with the study drug on Day 1.
  8. The participant has any medically diagnosed or suspected immune-deficiency condition.
  9. The participant has an immunocompromising condition or disease, or is currently undergoing a form of treatment or was undergoing a form of treatment that can be expected to influence immune response within 30 days prior to vaccination with the study drug.

    Such treatments include, but are not limited to, systemic or high dose inhaled corticosteroids (>800 μg/day of beclomethasone dipropionate or equivalent; the use of inhaled and nasal steroids that do not exceed this level will be permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.

  10. The participant has received antipyretics within 4 hours prior to vaccination with the study drug.
  11. The participant has a history of Guillain-Barré Syndrome, demyelinating disorders (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis), or convulsions.
  12. The participant has a functional or anatomic asplenia.
  13. The participant has a rash, other dermatologic conditions or tattoos that may interfere with the evaluation of local reaction.
  14. The participant has a past or present history of infection with the Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).
  15. The participant has a known hypersensitivity to any component of BLB-750.
  16. The participant has a history of severe allergic reactions or anaphylaxis.
  17. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol dependence within 1 year prior to vaccination with the study drug or is unwilling to agree to abstain from excessive alcohol and drugs throughout the study.
  18. The participant has received any blood product (e.g., blood transfusion or immunoglobulin) within 90 days prior to vaccination with the study drug.
  19. The participant has received any live vaccine within 4 weeks (28 days) prior to vaccination with the study drug or any inactivated vaccine within 2 weeks (14 days) prior to vaccination with the study drug.
  20. The participant is a pregnant or lactating woman or wishes to become pregnant before signing informed consent, during, or within 12 weeks after the last vaccination with the study drug or intends to donate ova during such time period.
  21. For males: The participant has donated whole blood ≥200 mL within 4 weeks (28 days) or ≥400 mL within 12 weeks (84 days) prior to the first vaccination with the study drug.

    For females: The participant has donated whole blood ≥200 mL within 4 weeks (28 days) or ≥400 mL within 16 weeks (112 days) prior to the first vaccination with the study drug.

  22. For males: The participant has donated whole blood ≥800 mL in total within 52 weeks (364 days) prior to the first vaccination with the study drug.

    For females: The participant has donated whole blood ≥400 mL in total within 52 weeks (364 days) prior to the first vaccination with the study drug.

  23. The participant has donated blood components within 2 weeks (14 days) prior to the first vaccination with the study drug.
  24. In the opinion of the investigator, the participant is unlikely to comply with protocol requirements or is considered ineligible for any other reason.
  25. The participant has presence of thrombocytopenia or coagulopathy, or has received anticoagulant therapy within 30 days prior to the first vaccination with the study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03370289


Locations
Layout table for location information
Japan
Sekino Rinsho Yakuri Clinic
Toshima-ku, Tokyo, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
  Study Documents (Full-Text)

Documents provided by Takeda:
Study Protocol  [PDF] November 21, 2017
Statistical Analysis Plan  [PDF] July 3, 2018

Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT03370289    
Other Study ID Numbers: BLB-750/CCT-901
U1111-1198-2695 ( Other Identifier: WHO )
JapicCTI-173797 ( Registry Identifier: JapicCTI )
First Posted: December 12, 2017    Key Record Dates
Results First Posted: July 29, 2019
Last Update Posted: July 29, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs